High-Yield Alert! Massive Rs 55 Final Dividend Declared; Watch For A Breakout Or Breakdown?

A division of the multinational pharmaceutical corporation Sanofi, Sanofi Consumer Healthcare India Ltd. is dedicated to offering over-the-counter (OTC) consumer healthcare products in India. Operating as a branch of the broader Sanofi India organisation, which also provides medicinal products in a number of therapeutic areas, is Sanofi Consumer Healthcare India. In the Indian pharmaceutical industry, Sanofi is a well-known brand that offers a wide range of medical treatments.

Sanofi Consumer Healthcare India Dividend

The Board of Directors "Recommended a final dividend of Rs. 55/- per equity share having face value of Rs.10/- each for the Financial Year ended 31st December 2024, subject to approval by shareholders of the Company at the ensuing Annual General Meeting (AGM). The Company shall inform in due course the record date / book closure for payment of dividend," said Sanofi Consumer Healthcare India in a stock exchange filing.

Sanofi Consumer Healthcare India Q3 Financials

In the December 2024 quarter, its net profit was Rs 44.3 crore, down 34.8% from Rs 67.9 crore in the same quarter the previous year. The company's revenues dropped from Rs 224.6 crore YoY to Rs 170.7 crore, a 24% drop in sales. Additionally, EBITDA decreased by 30.6% in Q4 to Rs 61.1 crore from Rs 89.5 crore in the year-ago quarter. Consequently, the company's EBITDA margin decreased from 39.9% YoY to 36.4%. In Q3 FY25, profit before tax was Rs 62.80 crore, a 2.6% increase over Q3 FY24's profit of Rs 61.20 crore. In Q3 of FY25, total operational expenses increased 13.8% year over year to Rs 111.50 crore.

Sanofi Consumer Healthcare India Share Price Target

Mandar Bhojane - Equity Research Analyst at Choice Broking said, " SANOFICONR is currently trading at 4592 and remains in a consolidation phase, moving within a defined range without a clear trend direction. The price has been fluctuating between support and resistance levels, reflecting market indecision. The Exponential Moving Averages (EMA) for 20, 50, and 100 days are positioned above the current price, confirming a slight bearish bias. The stock has remained below these key moving averages for an extended period, reinforcing the cautious outlook. Immediate resistance is observed at 4650, followed by 4707, which aligns with the 20-day EMA."

"On the downside, key support is located near 4537. A breakdown below this level could accelerate selling pressure, potentially leading to further declines. The Relative Strength Index (RSI) is currently at 31.86, indicating bearish momentum and suggesting that the stock remains under selling pressure. Despite occasional recovery attempts, the stock has struggled to gain traction, with no strong reversal signals at this stage. Traders should monitor price action closely for any signs of a breakout or further weakness before making strategic decisions," the analyst further recommended.

Disclaimer

The recommendations made above are by market analysts and are not advised by either the author, nor Greynium Information Technologies. The author, nor the brokerage firm nor Greynium would be liable for any losses caused as a result of decisions based on this write-up. Goodreturns.in advises users to consult with certified experts before making any investment decision.